Acknowledgments
We thank SignalRx Pharmaceutical, Inc. for providing SRX3305 and SRX3333 and The Ohio State University Leukemia Tissue Bank staff for primary patient sample procurement services that was supported by the National Cancer Institute grant P30 CA016058. We also thank the Department of Pharmacology and Experimental Neuroscience Elutriation Core at the University of Nebraska Medical Center for the isolation of healthy donor PBLs used in this study. We acknowledge Jinxu Liu for initial inhibitor testing in malignant B-cells lines.
Authors contribution
A.L.S., D.P., R.M.R., and A.P.E. performed the experiments and together with D.L.D., T.G.K., and D.E. analyzed the data. A.L.S., D.P. and D.E. wrote the initial manuscript draft. D.L.D., T.G.K., and D.E. supervised the study. T.G.K. and D.E. obtained funding to support the work. All authors have read and approved the final manuscript.
Disclosure statement
D.L.D. has an equity interest in SignalRx Pharmaceuticals, Inc., which has patent applications pending related to the multi-target inhibitors SRX3305 and SRX3333. All other authors declare no conflict of interest.
Correction Statement
This article has been republished with minor changes. These changes do not impact the academic content of the article.